• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2022 Fiscal Year Final Research Report

Effectiveness of RyR2 inhibitors as antiarrhytmic drugs

Research Project

  • PDF
Project/Area Number 19K07105
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 47040:Pharmacology-related
Research InstitutionJuntendo University

Principal Investigator

Kurebayashi Nagomi  順天堂大学, 医学部, 客員准教授 (50133335)

Co-Investigator(Kenkyū-buntansha) 森 修一  東京医科歯科大学, 生体材料工学研究所, 助教 (00467630)
村山 尚  順天堂大学, 医学部, 先任准教授 (10230012)
村越 伸行  筑波大学, 医学医療系, 准教授 (80447218)
Project Period (FY) 2019-04-01 – 2023-03-31
Keywordsリアノジン受容体 / 不整脈 / 心臓 / カルシウム / ドラッグスクリーニング
Outline of Final Research Achievements

Lethal arrhythmias caused by hyperactivation of the type 2 ryanodine receptor (RyR2) are predicted to be suppressed by RyR2 inhibitors. However, such RyR2-specific inhibitors do not yet exist, so this needs to be verified. First, we showed that disease-causing RyR2 mutations increase the cytoplasmic Ca2+ dependent RyR2 channel activity (i.e., CICR), which then determines the arrhythmia severity. We then performed high-throughput screening for RyR2 inhibitors followed by structural optimization, and finally found a RyR2-specific and high-affinity CICR inhibitor. In addition, we established validation procedures for antiarrhythmic effects using arrhythmia model mice harboring RyR2 mutations. Our novel RyR2 inhibitor efficiently suppressed arrhythmias in the model mice.

Free Research Field

薬理学

Academic Significance and Societal Importance of the Research Achievements

我々の結果は、これまで不整脈治療薬として存在しなかったRyR2阻害薬が新たなカテゴリーの抗不整脈薬となる可能性を示す。RyR2阻害薬は遺伝性不整脈疾患の特効薬となる可能性があるため、社会的意義は大きい。また、RyR2は中枢神経系など心臓以外の様々な臓器に発現しており、てんかんやアルツハイマー病への関与が提唱されているが、その詳細を研究する手段が少なかった。特異的RyR2阻害薬を世に出すことは、これらの重要な疾患の機序解明にも貢献するため、学術的な意義も大きい。

URL: 

Published: 2024-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi